MedPath

Effect of ayurvedic lepa preparations in the management of melasma(vyanga).

Phase 2
Conditions
Health Condition 1: L811- Chloasma
Registration Number
CTRI/2021/04/032828
Lead Sponsor
ational institute of ayurveda
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Subjects of either sex with age group above 18

years will be selected.

2.Subjects with Fitzpatrick skin types III, IV and V presenting with the classical signs and

symptoms of Vyaá¹?ga(melasma) will be selected.

3.Subjects willing to participate in the study and willing to give written informed consent will be selected by explaining the interventions in detail.

4.Female subjects of childbearing potential using

a reliable from of contraception during the course of the study excluding oral contraceptive

pills at the time of the study or in the past 6

months (intrauterine device or condoms) or female of nonchildbearing potential (hysterectomy, bilateral ovariectomy or tubal section/ligation).

5.Female subjects of childbearing potential with a negative urine pregnancy test before inclusion

in the study.

Exclusion Criteria

1.Hyperpigmentation caused since birth like nevus of ota.

2.Hyperpigmentation caused by tumor like malignant melanoma.

3.Vya�ga along with other kuṣṭha roga to be excluded.

4.Pregnant women, nursing mothers.

5.Subjects suffering from other pigmentation

disorders.

6.Subject having used any cosmetic depigmenting

agent within 2 weeks prior to inclusion.

7.Subjects who have used a topical or inhaled

corticosteroid or systemic steroids within 1 month prior to inclusion in the study.

8.Subjects having used topical tretinoin within 3 months or topical hydroquinone within 6 months prior to inclusion.

9.Subjects with history of endocrinopathies.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in classical signs and symptoms of vyaá¹?ga.Timepoint: 45 days
Secondary Outcome Measures
NameTimeMethod
Better quality of life.Timepoint: 45 days
© Copyright 2025. All Rights Reserved by MedPath